Osteoporosis: managing the non-generic patient

Osteoporosis is a chronic disease affecting the whole skeleton, causing bones to become more fragile, and increasing the risk of fracture. Having one fracture increases the risk of future fractures, so patients who have had a fracture need assessment and many need therapy. Both the National Institute for Health and Clinical Excellence (NICE) and the National Osteoporosis Guideline Group (NOGG) recommend generic alendronic acid (AA) as first-line therapy due to cost effectiveness.